Malvern explores rheology for protein formulation at 2nd Protein-Protein Interaction Conference
Malvern Instruments will contribute a scientific poster at the 2014 Protein-Protein Interaction Conference, 23–24 October, Boston, MA, USA. The poster describes new work on rheological approaches to protein stability studies during biologics formulation and will be presented by Matt McGann, Malvern Instruments Life Science Sales and Application Specialist for the Americas.
The study of rheology in protein formulation and biotherapeutic development is considered to be a developing and ultimately essential measurement. The Malvern presentation ‘Characterising the stability of protein solutions using rheological techniques’ outlines the approaches required to characterise the total rheological properties of a protein formulation. This includes rotational rheology, capillary viscometry and dynamic light scattering (DLS) microrheology. Data are compared with those from other widely used analytical techniques for protein studies, such as DLS and gel permeation chromatography (GPC), to illustrate that rheological properties are useful predictive measures of formulation stability.
Capillary microviscometry is a technique that is well-suited for high throughput screening studies, while rotational rheology and DLS microrheology are more applicable for determining the viscoelastic properties of non-Newtonian fluids, as they are able to interrogate a wide range of shear rates and angular frequencies. In combination, these techniques generate a comprehensive rheological profile for a protein formulation during early phase screening. This has proven a valuable guide for predicting the stability, and hence suitability, of a biotherapeutic target.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.